Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
LGND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$67.72 - $129.90
Previous CloseN/A
Volume21.09K
Average Volume (3M)91.03K
Market Cap
$2.31B
Enterprise Value$1.63B
Total Cash (Recent Filing)$718.38M
Total Debt (Recent Filing)$636.30M
Price to Earnings (P/E)48.0
Beta1.41
Next Earnings
Apr 30, 2025EPS Estimate
1.23Last Dividend Ex-Date
Nov 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding18,895,372
10 Day Avg. Volume127,456
30 Day Avg. Volume91,030
Standard Deviation0.17
R-Squared0.11
Alpha0.01
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)N/A
Price to Sales (P/S)15.15
Price to Cash Flow (P/CF)15.80
P/FCF Ratio16.10
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.95
Enterprise Value/Ebitda-128.11
Forecast
1Y Price Target
$149.80Price Target Upside22.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Ligand Pharma News
PremiumCompany Announcements
Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth
PremiumCompany Announcements
Ligand Pharmaceuticals Reports Strong 2024 Financial Growth
PremiumCompany Announcements
Ligand Pharma Enters $75M Agreement with Castle Creek
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLigand reported positive financial results for their 4Q24, including revenues of $42.8 million, up from $28.1 million one year ago, and adjusted earnings per share of $1.27 compared with $1.05 in 4Q23.
Royalty RevenueRoyalty revenue is expected to see meaningful growth based on new products like Filspari, Qarziba, and Ohtuvayre.
Bears Say
Revenue StabilityThere is a long-term theme of choppiness quarter over quarter regarding Captisol sales and contract revenue based almost entirely on the timing of orders and milestone payments.
---
Ownership Overview
2.49% Insiders
38.06% Mutual Funds
25.79% Other Institutional Investors
6.07% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LGND FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was $67.72 and its highest was $129.90 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is $2.31B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is Apr 30, 2025 which is in 57 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Feb 27, 2025. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.08.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of $30.012 which represents an annual dividend yield of N/A. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.23.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 18,895,372 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of $1.27 in its last earnings report, beating expectations of $1.19. Following the earnings report the stock price went up 0.574%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in LGND
---
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$149.80 (22.56% Upside)
$149.80 (22.56% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 109.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $244.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.90%
12-Months-Change
Fundamentals
Return on Equity
-0.53%
Trailing 12-Months
Asset Growth
19.63%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
---
LGND Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong financial growth and strategic achievements, highlighted by significant increases in revenue and successful product launches. Despite some financial setbacks related to non-cash impairments and increased operating expenses, Ligand's robust financial position and promising investment pipeline indicate a positive outlook.Read More>---
LGND Stock 12 Month Forecast
Average Price Target
$149.80
▲(22.56% Upside)
Technical Analysis
Best Analysts Covering LGND
1 Year
1 Year Success Rate
22/31 ratings generated profit
1 Year Average Return
+15.77%
reiterated a buy rating 6 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 70.97% of your transactions generating a profit, with an average return of +15.77% per trade.
---